Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Ceribell focuses on making electroencephalography accessible, efficient, and cost-effective.
Allakos is a biotechnology company developing therapeutic antibodies targeting allergy, inflammatory and proliferative diseases.
Strand Therapeutics is a biopharmaceutical company applying synthetic biology to RNA therapeutics to develop single dose mRNA treatments.
Prime Medicine is a biotechnology company that utilizes Prime Editing to modify genetic sequences to treat a wide range of diseases.
Quantum SI offers Next Generation Protein Sequencing that makes diagnostics digital.
Annexon Biosciences is a biotech company, discovering and developing novel therapeutics for neurodegenerative and autoimmune disorders.
Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.
GRO Biosciences is a biotechnology company that develops a protein therapeutics technology to improve treatments across multiple diseases.
Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.
We provide simple, sophisticated respiratory solutions for post-ICU and home environments, eliminating unnecessary cost and complexity.
Blueprint Medicines develops precision therapies for genomically defined cancers and rare diseases.
Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.
Nuvation Bio is a global biopharmaceutical company focusing on unmet needs in oncology.
ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer.
Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
IGM Biosciences is a biotechnology company that develops medicine for people with infectious infections, autoimmune diseases, and cancer.
One Biosciences leverages single-cell technologies to identify new therapeutics for difficult-to-treat diseases.
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease.
Zentalis is a pharmaceutical company focused on developing clinical therapeutics for cancer patients.
Shattuck Labs is a biotechnology company that provides novel class biologic medicines for the treatment of cancer and autoimmune disease.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
ElevateBio is a biotechnology company that specializes in cell and gene-based therapies.
Redmile Group has invested in 104 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Redmile Group's top investment sectors include Biotechnology, Health Care, Therapeutics, Life Science, Medical. The firm invests across 19 different industry categories.
Among tracked funding rounds, Blueprint Medicines received $1.3B in a Post-IPO Equity round. Redmile Group's total known invested capital is $12.5B.
Redmile Group's average investment size is $136.1M across its portfolio of 104 companies.
Recent Redmile Group portfolio additions include Ceribell, Allakos, Strand Therapeutics, Prime Medicine, Quantum SI. These companies were founded in 2020 or later.